← Back to Clinical Trials
Recruiting NCT07285564

NCT07285564 Performance of 18F-FDG Micro-PET-CT in the Assessment of Surgical Margins in Head and Neck Cancer

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07285564
Status Recruiting
Phase
Sponsor Centre Henri Becquerel
Condition Head & Neck Cancer
Study Type INTERVENTIONAL
Enrollment 10 participants
Start Date 2025-11-07
Primary Completion 2026-03-15

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
micro PET/CT

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 10 participants in total. It began in 2025-11-07 with a primary completion date of 2026-03-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to evaluate the diagnostic performance of 18F-FDG micro-PET-CT in malignant Head and neck cancer compared to definitive histological analysis (gold standard).

Eligibility Criteria

Inclusion Criteria: * Signed informed consent * Adult, male or female, aged 18 or over * Patient with a malignant tumor of the oral cavity, oropharynx, hypopharynx, larynx, sinuses, or salivary glands, regardless of lymph node status (any N) M0, operable * Member or beneficiary of a social security plan Exclusion Criteria: * Child-Pugh C liver failure * Patients under guardianship, conservatorship, or legal protection * Patients deprived of their liberty * Pregnant or breastfeeding women * Hypersensitivity to 18F-FDG or any of its excipients (ethanol or water for injection) * Uncontrolled diabetes * Moderate to end-stage renal failure, stage IIIB to V (glomerular filtration rate less than 44 mL/min/1.73 m²) * Patients unable to understand the study for any reason or to comply with the trial requirements (language, psychological, or geographical issues).

Contact & Investigator

Central Contact

Lise-Marie Roussel, MD

✉ lise-marie.roussel@chb.unicancer.fr

📞 +33232082222

Principal Investigator

Sebastien Hapdey, PhD

PRINCIPAL INVESTIGATOR

Centre Henri Becquerel

Frequently Asked Questions

Who can join the NCT07285564 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Head & Neck Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07285564 currently recruiting?

Yes, NCT07285564 is actively recruiting participants. Contact the research team at lise-marie.roussel@chb.unicancer.fr for enrollment information.

Where is the NCT07285564 trial being conducted?

This trial is being conducted at Rouen, France.

Who is sponsoring the NCT07285564 clinical trial?

NCT07285564 is sponsored by Centre Henri Becquerel. The principal investigator is Sebastien Hapdey, PhD at Centre Henri Becquerel. The trial plans to enroll 10 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology